 | | | | Related Healthscout Videos | |
|
Page: << Prev | 1 | 2 Over the four years of the trial, the researchers found that patients treated with tiotropium had better scores on the St. George's Respiratory Questionnaire, a measure of lung function, compared with patients taking placebo. Those receiving tiotropium also had reductions in the risk of exacerbations, hospitalization and respiratory failure.
Exacerbations associated with COPD include worsening symptoms such as shortness of breath. Often these worsening symptoms require hospitalization and changes in medication.
However, treatment with tiotropium did not improve forced expiratory volume (FEV1), which is a measure of breathing and a marker for the progression of COPD. Throughout the study, FEV1 continued to decline in both groups.
Text Continues Below
"However, the rate of decline of lung function may have reached a ceiling as the values observed were lower than those reported in other trials," Celli said.
Dr. Barry Make, director of the COPD program at National Jewish Health in Denver, thinks the study demonstrates the safety and effectiveness of tiotropium in improving patient's lives.
"Tiotropium, when added to usual therapy, did not demonstrate a reduction in the normal decline in FEV1," Make said. "But the study did confirm other findings from the past, including improved quality of life and reductions in exacerbations."
Exacerbations affect quality of life, decrease lung function, and have significant long-term and short-term consequences, Make said. "So, exacerbations are a major issue," he added.
"What limits patients, and what patients complain about, is the shortness of breath and the associated detriments to the quality of life," Make said. "So, from a patient perspective, these are two things important things that modify the impact of the disease."
Make noted that there have been questions about the side effects associated with tiotropium, including an increased risk of heart attack and stroke, but this study lays these fears to rest. "In this large study, there are no safety signals," he said.
More information
For more about COPD, visit the U.S. National Heart, Lung, and Blood Institute.
Page: << Prev | 1 | 2
|
.gif)
